Pensionfund Sabic Sells 5,500 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Pensionfund Sabic reduced its stake in Gilead Sciences by 22.0%, owning 19,500 shares valued at approximately $2,185,000 after selling 5,500 shares in the first quarter.
• Gilead Sciences reported $2.01 earnings per share for the last quarter, exceeding expectations, and their revenue increased 1.4% year-over-year to $7.08 billion.
• The company recently announced a quarterly dividend of $0.79 per share, with a yield of 2.8%, to be paid on September 29th.

Pensionfund Sabic lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 22.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,500 shares of the biopharmaceutical company's stock after selling 5,500 shares during the quarter. Pensionfund Sabic's holdings in Gilead Sciences were worth $2,185,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. AG2R LA Mondiale Gestion D Actifs acquired a new stake in Gilead Sciences during the 1st quarter worth about $5,100,000. Swedbank AB lifted its stake in Gilead Sciences by 0.8% in the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock worth $237,393,000 after purchasing an additional 16,663 shares in the last quarter. Voya Investment Management LLC raised its position in shares of Gilead Sciences by 104.2% during the 1st quarter. Voya Investment Management LLC now owns 1,667,799 shares of the biopharmaceutical company's stock valued at $186,877,000 after buying an additional 850,906 shares during the period. Optima Capital LLC purchased a new stake in Gilead Sciences in the first quarter valued at approximately $210,000. Finally, 1248 Management LLC acquired a new position in shares of Gilead Sciences in the first quarter worth $50,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $2.01 during mid-day trading on Monday, reaching $112.54. 6,168,790 shares of the company were exchanged, compared to its average volume of 5,710,857. The stock has a market cap of $139.64 billion, a PE ratio of 22.42, a PEG ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83. The company has a fifty day moving average of $114.05 and a 200 day moving average of $110.06.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the company posted $2.01 EPS. The business's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares of the company's stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 76,500 shares of company stock valued at $8,765,395 in the last ninety days. 0.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on GILD shares. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.